APP and Alzheimer disease: Approximately 15% of pharmacological studies searching for anti-AD drugs focused on anti-amyloidogenic strategies (immunotherapy, APP modulators, α-secretase modulators, β-secretase (BACE) inhibitors, Υ-secretase modulators, Aβ aggregation inhibitors, Notch inhibitors, β-sheet breakers, and Aβ scavengers), with notorious failures [101].